Genescient Corporation, a California genomic-health biotechnology company, received $500,000 in new angel investment, to help commercialize the company’s technology and to fund further research.
Gregory Benford, Chairman of the Board of Genescient Corporation, will discuss Genescient’s approach to expanded longevity and will discuss some of its latest results, at The Singularity Summit 09.
Genescient study suggests that, when long-term effects are considered, two commonly ingested stimulants are not created equal. Caffeine consistently impaired mating success in Genescient’s experiments, as-well-as survival and female reproduction. Theobromine was benign.
Genescient Corporation and Kronos Science Laboratory will work together to analyze the Kronos Alzheimer’s Case-Control Database, considered to be the finest Alzheimer’s Disease genetic data set in the US. The companies hope to identify genes previously unrecognized genes that are involved in Alzheimer’s Disease.